 Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 | | 2005 | 0 | 3 | 3 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 0 | 1 | | 2013 | 3 | 2 | 5 | | 2014 | 2 | 0 | 2 | | 2015 | 3 | 0 | 3 | | 2016 | 2 | 0 | 2 | | 2017 | 0 | 2 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 1 | 2 | | 2021 | 1 | 2 | 3 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 | | 2024 | 1 | 0 | 1 | | 2025 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Zambrano LD, Simeone RM, Newhams MM, Payne AB, Halasa NB, Orzel-Lockwood AO, Calixte JM, Kamidani S, Crandall H, Cameron MA, Schuster JE, Maddux AB, Chiotos K, Irby K, Shein SL, Staat MA, Martin LM, Bhumbra SS, Nofziger RA, Chauhan JC, Zerr DM, Gertz SJ, Guzman-Cottrill JA, Kong M, Hume JR, Coates BM, Michelson KN, Levy ER, Bradford TT, Schwartz SP, Walker TC, Stockwell MS, Biggs A, Hogan AH, Lindsey K, Campbell AP, Randolph AG. Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025. MMWR Morb Mortal Wkly Rep. 2025 Nov 20; 74(37):580-588.
-
Khan AA, Ali DS, Appelman-Dijkstra NM, Carpenter TO, Chaussain C, Imel EA, Jan de Beur SM, Florenzano P, Abu Alrob H, Aldabagh R, Alexander RT, Alsarraf F, Beck-Nielsen SS, Biosse-Duplan M, Cohen-Solal M, Crowley RK, Dandurand K, Filler G, Friedlander L, Fukumoto S, Gagnon C, Goodyer P, Grasemann C, Grimbly C, Hussein S, Javaid MK, Khan S, Khan A, Lehman A, Lems WF, Lewiecki EM, McDonnell C, Mirza RD, Morgante E, Morrison A, Portale AA, Rhee Y, Rush ET, Siggelkow H, Tetradis S, Tosi L, Ward LM, Guyatt G, Brandi ML. X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab. 2025 Jul 15; 110(8):2353-2370.
-
Patton ME, Moline HL, Whitaker M, Tannis A, Pham H, Toepfer AP, Taylor CA, Goldstein L, Reingold A, Kirley PD, Alden NB, Kawasaki B, Meek J, Kim D, Witt LS, Openo KP, Ryan PA, Mumm E, Lynfield R, Salazar-Sanchez Y, Pacheco F, Keating F, Anderson BJ, Tesini BL, Felsen CB, Sutton M, Thomas A, Schaffner W, Talbot HK, Harbi K, Doran E, Weinberg GA, Staat MA, Payne DC, Halasa NB, Stewart L, Boom JA, Sahni LC, Klein EJ, Englund JA, Williams JV, Michaels MG, Schuster JE, Selvarangan R, Szilagyi PG, Havers FP, Dawood FS. Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 May 08; 74(16):273-281.
-
Moline HL, Toepfer AP, Tannis A, Weinberg GA, Staat MA, Halasa NB, Boom JA, Klein EJ, Williams JV, Schuster JE, Goldstein L, McKeever ER, Kalman C, Paden C, Atherton L, Aggarwal M, Roychoudhury P, Piedra PA, Sahni LC, Stewart LS, Selvarangan R, Michaels MG, Schlaudecker EP, Szilagyi PG, Englund JA, Clopper BR, Thornburg NJ, Derado G, McMorrow ML, Dawood FS. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
-
Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R, Michaels MG, Sahni LC, Klein EJ, Stewart LS, Schlaudecker EP, Szilagyi PG, Schuster JE, Goldstein L, Musa S, Piedra PA, Zerr DM, Betters KA, Rohlfs C, Albertin C, Banerjee D, McKeever ER, Kalman C, Clopper BR, McMorrow ML, Dawood FS. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
-
Caserta MT, O'Leary ST, Munoz FM, Ralston SL. Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics. 2023 Jul 01; 152(1).
-
Ashrafzadeh-Kian SL, Ito N, Srivastava T, Garg U, Kato H, Algeciras-Schimnich A, Bornhorst JA. The effect of burosumab on intact and C-terminal FGF23 measurements. Clin Endocrinol (Oxf). 2023 08; 99(2):152-157.
-
Gbadamosi MO, Shastri VM, Elsayed AH, Ries R, Olabige O, Nguyen NHK, De Jesus A, Wang YC, Dang A, Hirsch BA, Alonzo TA, Gamis A, Meshinchi S, Lamba JK. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials. Leukemia. 2022 08; 36(8):2022-2031.
-
Escobar M, Dunn A, Quon D, Trzaskoma B, Lee L, Ko RH, Carpenter SL. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia. 2022 07; 28(4):e105-e108.
-
Singh AK, Oks M, Husk G, Dechario SP, Mina B, Singh K, Kirschenbaum L, Carpati CM, Mahmoud O, Gabra NI, Ishikawa O, Altschultz E, Shah V, Mahajan A, Gautam A, Birnbaum B, Antonacci AC, Raoof S. Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection. Respir Care. 2021 12; 66(12):1805-1814.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|